Toxic erythema of chemotherapy

  • 1  Bolognia JL, Cooper DL, Glusac EJ. Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 2008;59(3):524–9. Cross Ref link Pubmed link
  • 2  Choi JN. Chemotherapy‐induced iatrogenic injury of skin: new drugs and new concepts. Clin Dermatol 2011;29(6):587–601. Cross Ref link Pubmed link
  • 3  Martorell‐Calatayud A, Sanmartín O, Botella‐Estrada R, et al. Chemotherapy‐related bilateral dermatitis associated with eccrine squamous syringometaplasia: reappraisal of epidemiological, clinical, and pathological features. J Am Acad Dermatol 2011;64(6):1092–103. Cross Ref link Pubmed link
  • 4  Valks R, Fraga J, Porras‐Luque J, et al. Chemotherapy induced eccrine squamous syringometaplasia. Arch Dermatol 1997;133:873–8. Cross Ref link Pubmed link
  • 5  Bhawan J, Malhortra R. Syringosquamous metaplasia: a distinctive eruption in patients receiving chemotherapy. Am J Dermatopathol 1990;12:1–6. Cross Ref link Pubmed link
  • 6  Baak BR, Burgdorf WHC. Chemotherapy‐induced acral erythema. J Am Acad Dermatol 1991;24:457–61. Cross Ref link Pubmed link
  • 7  Cohen PR. Acral erythema: a clinical review. Cutis 1993;51:175–9. Pubmed link
  • 8  Webber KA, Kos L, Holland KE, et al. Intertriginous eruption associated with chemotherapy in pediatric patients. Arch Dermatol 2007;143:67–71. Pubmed link
  • 9  Korver GE, Ronald H, Petersen MJ. An intertrigo‐like eruption from pegylated liposomal doxorubicin. J Drugs Dermatol 2006;5:901–2. Pubmed link
  • 10  Susser WS, Whitaker‐Worth DL, Grant‐Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999;40:367–98. Cross Ref link Pubmed link
  • 11  Thorisdottir K, Tomecki KJ, Bergfeld WF, et al. Neutrophilic eccrine hidradenitis. J Am Acad Dermatol 1993;28:775–7. Cross Ref link Pubmed link

Papulopustular eruptions

  • 12  Nanney LB, Stoscheck CM, King LE, et al. Immunolocalization of epidermal growth factor receptors in normal developing human skin. J Invest Dermatol 1990;94:742–8. Cross Ref link Pubmed link
  • 13  Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006;6:803–12. Cross Ref link Pubmed link
  • 14  Brodell LA, Hepper D, Lind A, et al. Histopathology of acneiform eruptions in patients treated with epidermal growth factor receptor inhibitors. J Cutan Pathol 2013;40(10):865–70. Pubmed link
  • 15  Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor‐associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist 2007;12(5):610–21. Cross Ref link Pubmed link
  • 16  Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event‐specific grading scale from the MASCC Skin Toxicity Study Group. Support Care Cancer 2010;18:509–22. Cross Ref link Pubmed link
  • 17  Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor‐associated dermatologic toxicities. Support Care Cancer 2011;19:1079–95. Cross Ref link Pubmed link
  • 18  Choi JN. Chemotherapy induced iatrogenic injury of skin: new drugs and new concepts. Clin Dermatol 2011; 29: 587–601 Cross Ref link Pubmed link
  • 19  Perez‐Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR targeted agents: is there a silver lining? J Clin Oncol 2005;23:5235–46. Cross Ref link Pubmed link
  • 20  Lacouture ME, Mitchell EP, Piperdi B, et al. Skin Toxicity Evaluation Protocol with Panitumumab (STEPP), a phase II, open label, randomised trial evaluating the impact of a pre‐emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 2010;28:1351–7. Cross Ref link Pubmed link
  • 21  Scope A, Agero AL, Dusza SW, et al. Randomized double blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab‐associated acne like eruption. J Clin Oncol 2006;4:236–8.
  • 22  Gutzmer R, Werfel T, Mao R, et al. Successful treatment with oral isotretinoin of acneiform skin lesions associated with cetuximab therapy. Br J Dermatol 2005;153:849–51. Cross Ref link Pubmed link

Chemotherapy‐induced hair changes

    Chemotherapy‐induced alopecia

    • 23  Chon SY, Champion RW, Geddes ER, Rashid RM. Chemotherapy‐induced alopecia. J Am Acad Dermatol 2012;67(1):e37–47. Cross Ref link Pubmed link
    • 24  Trueb RM. Chemotherapy‐induced alopecia. Semin Cutan Med Surg 2009;28(1):11–14. Cross Ref link Pubmed link
    • 25  Paus R, Haslam IS, Sharov AA, et al. Pathobiology of chemotherapy‐induced hair loss. Lancet Oncol 2013;14:e50–9. Cross Ref link Pubmed link
    • 26  Lacouture ME, Anadkat MJ, Bensadoun R‐J, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor‐associated dermatologic toxicities. Support Care Cancer 2011;19:1079–95. Cross Ref link Pubmed link
    • 27  Yeager CE, Olsen EA. Treatment of chemotherapy‐induced alopecia. Dermatol Ther 2011;24:432–42. Cross Ref link Pubmed link
    • 28  Grevelman EG, Breed PM. Prevention of chemotherapy‐induced hair loss by scalp cooling. Ann Oncol 2005;16:352–8. Cross Ref link Pubmed link

    Chemotherapy‐induced hypertrichosis

    • 29  Mak KK, Chan SY. Epidermal growth factor as a biologic switch in hair growth cycle. J Biol Chem 2003;278:26120–6. Cross Ref link Pubmed link
    • 30  Galimont‐Collen AFS, Vos LE, Lavrijsen APM, et al. Classification and management of skin, hair, nail and mucosal side‐effects of epidermal growth factor receptor (EGFR) inhibitors. Eur J Cancer 2007;43:845–51. Cross Ref link Pubmed link
    • 31  Dueland S, Sauer T, Lund‐Johansen F, et al. Epidermal growth factor receptor inhibition induces trichomegaly. Acta Oncol 2003;42(4):345–6. Cross Ref link Pubmed link
    • 32  Pascual JC, Banuls J, Belinchon I, et al. Trichomegaly following treatment with gefitinib (ZD1839). Br J Dermatol 2004;151:111–12. Cross Ref link
    • 33  Choi JN. Chemotherapy induced iatrogenic injury of skin: new drugs and new concepts. Clin Dermatol 2011;29:587–601. Cross Ref link Pubmed link

    Chemotherapy‐induced nail changes

    • 34  Garden BC, Wu S, Lacouture ME. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta‐analysis. Am Acad Dermatol 2012;67:400–8. Cross Ref link
    • 35  Minisini A, Tosti A, Sobrero A, et al. Taxane‐induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 2003;14;333–7. Cross Ref link Pubmed link
    • 36  Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event‐specific grading scale from the MASCC Skin Toxicity Study Group. Support Care Cancer 2010;18:509–22. Cross Ref link Pubmed link
    • 37  Eames T, Grabein B, Kroth J, et al. Microbiological analysis of epidermal growth factor receptor inhibitor therapy‐associated paronychia. J Eur Acad Dermatol Venereol 2010;24:958–60. Cross Ref link Pubmed link
    • 38  Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor‐associated dermatologic toxicities. Support Care Cancer 2011;19:1079–95. Cross Ref link Pubmed link
    • 39  Susser WS, Whitaker‐Worth DL, Grant‐Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999;40:367–98. Cross Ref link Pubmed link
    • 40  Hedary N, Naik H, Burgin S. Chemotherapeutic agents and the skin: an update. J Am Acad Dermatol 2008:58:545–70. Cross Ref link Pubmed link
    • 41  Prabhash K, Biswas G, Prasad N, Karant N, Sastry PS, Prikh PM. Imatinib‐induced nail hyperpigmentation in chronic myeloid leukaemia. Indian J Dermatol Venereol Leprol 2006;72:63–4. Cross Ref link Pubmed link
    • 42  Perry C, Doll D, Freter C. Perry's The Chemotherapy Source Book. Philadelphia: Lippincott Williams and Wilkins, 2012.

    Dyspigmentation

    • 43  Alley E, Green R, Schuchter L. Cutaneous toxicities of cancer therapy. Curr Opin Oncol 2002;14:212–16. Cross Ref link Pubmed link
    • 44  Ibrahimi O, Anderson R. Bleomycin‐Induced flagellate hyperpigmentation. N Engl J Med 2010;363:e36. Cross Ref link Pubmed link
    • 45  Ziemer M, Goetze S, Juhasz K, et al. Flagellate dermatitis as a bleomycin‐specific adverse effect of cytostatic therapy. Am J Clin Dermatol 2011;12:68–76. Cross Ref link Pubmed link
    • 46  Lazo JS, Humphreys CJ. Lack of metabolism as the biochemical basis of bleomycin‐induced pulmonary toxicity. Proc Natl Acad Sci USA 1983;80:3064–8. Cross Ref link Pubmed link
    • 47  Lindley C. Adverse effects of chemotherapy. In: Koda‐Kimble MA, Young LY, Kradjan W, eds. Applied Therapeutics: The Clinical Use of Drugs, 8th edn. Philadelphia: Lippincott Williams and Wilkins, 2005.
    • 48  Rao MV, Shayne M. Vitiligo in the affected breast during neo‐adjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2009;117:197–8. Cross Ref link Pubmed link
    • 49  Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF‐KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol 1998;111:233–8. Cross Ref link Pubmed link
    • 50  Gowda S, Tillman DK, Fitzpatrick JE, Gaspari AA, Goldenberg G. Imiquimod‐induced vitiligo after treatment of nodular basal cell carcinoma. J Cutan Pathol 2009;36(8):878–81. Cross Ref link Pubmed link
    • 51  Jalalat S, Cohen P. Gefitinib‐associated vitiligo: report in a man with partoid squamous cell carcinoma and review of drug‐induced hypopigmentation. Dermatol Online J 2013;19(10):20020. Pubmed link

    Photosensitivity

    • 52  Dawe RS, Ibbortson SH. Drug induced photosensitivity. Dermatol Clin 2014;32:363–8. Cross Ref link Pubmed link
    • 53  Ferguson J. Photosensitivity due to drugs. Photodermatol Photoimmunol Photomed 2002;18:262–9. Cross Ref link Pubmed link
    • 54  Moore DE. Drug induced cutaneous photosensitivity, incidence, mechanism, prevention and management. Drug Saf 2002;25(2):345–72. Cross Ref link Pubmed link
    • 55  Gould JW, Mercurio MG, Elmets CA. Cutaneous photosensitivity diseases induced by exogenous agents. J Am Acad Dermatol 1995;33(4):51–73. Cross Ref link
    • 56  Gonzalez E, Gonazalez S. Drug photosensitivity, idiopathic photodermatoses and sunscreens. J Am Acad Dermatol 1996;35(6):871–85. Cross Ref link Pubmed link
    • 57  Susser WS, Whitaker‐Worth DL, Grant‐Kels JM. Mucocutaneous reactions to chemotherapy. J Am Acad Dermatol 1999;40(3):367–98. Cross Ref link Pubmed link
    • 58  Yung CW, Winston EM, Lorincz AL. Dacarbazine induced photosensitivity reaction. J Am Acad Dermatol 1981;4:541–3. Cross Ref link Pubmed link
    • 59  Gelot P, Dutartre H, Khammari A, et al. Vemurafenib: an unusual UVA‐induced photosensitivity. Exp Dermatol 2013;4:297–8. Cross Ref link

    Recall reaction

    • 60  Azria D, Magne N, Zouhair A, et al. Radiation recall: a well recognized but neglected phenomenon. Cancer Treat Rev 2005;31:555–70. Cross Ref link Pubmed link
    • 61  Caloglu M, Yurut‐Caloglu V, Cosar‐Alas R, et al. An ambiguous phenomenon of radiation and drugs: recall reactions. Onkologie 2007;30:209–14. Cross Ref link Pubmed link
    • 62  Camidge R, Price A. Characterizing the phenomenon of radiation recall dermatitis. Radiother Oncol 2001;59:237–45. Cross Ref link Pubmed link
    • 63  Kodym E, Kalinska R, Ehringfeld C, et al. Frequency of radiation recall dermatitis in adult cancer patients. Onkologie 2005;28:18–21. Cross Ref link Pubmed link
    • 64  Smith KJ, Germain M, Skelton H. Histopathologic features seen with radiation recall or enhancement eruptions. J Cutan Med Surg 2002;6:535–40. Cross Ref link Pubmed link
    • 65  Hird A, Wilson J, Symons S, Sinclair E, Davis M, Chow E. Radiation recall dermatitis: case report and review of the literature. Curr Oncol 2008;15(1):53–62. Cross Ref link Pubmed link
    • 66  Yeo W, Johnson PJ. Radiation‐recall skin disorders associated with the use of antineoplastic drugs. Pathogenesis, prevalence, and management. Am J Clin Dermatol 2000;1:113–16. Cross Ref link Pubmed link
    • 67  Burris H, Hurtig J. Radiation recall with anticancer agents. Oncologist 2010;15:1227–37. Cross Ref link Pubmed link

    Radiotherapy‐associated skin side effects

    • 68  Dehen L, Vilmer C, Humilière C, et al. Chronic radiodermatitis following cardiac catheterisation: a report of two cases and a brief review of the literature. Heart 1999;81(3):308–12. Cross Ref link Pubmed link
    • 69  Nahass GT. Acute radiodermatitis after radiofrequency catheter ablation. J Am Acad Dermatol 1997;36:881–4. Cross Ref link Pubmed link
    • 70  Schnur JB, Love B, Scheckner BL, Green S, Wernicke AG, Montgomery GH. A systematic review of patient‐rated measures of radiodermatitis in breast cancer radiotherapy. Am J Clin Oncol 2011;34(5):529–36. Pubmed link
    • 71  Bernier J, Bonner J, Vermorken JB, et al. Consensus guidelines for the management of radiation dermatitis and coexisting acne‐like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 2008;19(1):142–9. Cross Ref link Pubmed link
    • 72  Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamouscell carcinoma of the head and neck. N Engl J Med 2006;354:567–78. Cross Ref link Pubmed link
    • 73  Hymes SR, Strom EA, Fife C. Radiation dermatitis: clinical presentation, pathophysiology, and treatment 2006. J Am Acad Dermatol 2006;54:28–46. Cross Ref link Pubmed link
    • 74  Muller K, Meineke V. Radiation‐induced alterations in cytokine production by skin cells. Exp Hematol 2007;35:96–104. Cross Ref link Pubmed link
    • 75  Bolderston A, Lloyd NS, Wong RK, et al. The prevention and management of acute skin reactions related to radiation therapy: a systematic review and practice guideline. Support Care Cancer 2006;14:802–17. Cross Ref link Pubmed link
    • 76  Flucke U, Requena L, Mentzel T. Radiation‐induced vascular lesions of the skin: an overview. Adv Anat Pathol 2013;20(6):407–15. Cross Ref link Pubmed link
    • 77  Lim D, Johnston S, Novakovic L, Fearfield L. Radiation‐induced morphoea treated with UVA‐1 phototherapy. Clin Exp Dermatol 2014;39(5):612–15. Cross Ref link Pubmed link
    • 78  Laetsch B, Hofer T, Lombriser N, Lautenschlager S. Irradiation‐induced morphea: x‐rays as triggers of autoimmunity. Dermatology 2011;223(1):9–12. Cross Ref link Pubmed link
    • 79  Fearfield LA, Bunker CB. Radiotherapy and erythema nodosum. Br J Dermatol 2000;142(1):189. Cross Ref link Pubmed link
    • 80  Vajrala G, Jain P, Surana S, Fernandes D. Generalized vitiligo post radiotherapy in a breast cancer patient. J Cancer Res Ther 2014;10(2):365–7. Cross Ref link Pubmed link
    • 81  Anusheel M, Sandeep J, Ashwini B, Rakesh J, Rajiv S. Radiotherapy‐induced depigmentation in a patient with breast cancer. Indian J Cancer 2007;44(4):157–8. Cross Ref link Pubmed link
    • 82  Weitzen R, Pfeffer R, Mandel M. Benign lesions in cancer patients: case 3. Vitiligo after radiotherapy for breast cancer in a woman with depigmentation disorder. J Clin Oncol 2005;23(3):644. Cross Ref link Pubmed link